The recent introduction of PET/CT using a PSMA radioligand for imaging of PCa BCR has shown promising results due to its performance in detecting lesions, even at very low PSA levels, impacting on the therapeutic management of PCa patients [12,13,14]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.